Livi Post-Sex Vaginal Device: Hmmmm

Dr. Chapa delivers a quick, candid episode on Livy, the first FDA-cleared post-intercourse vaginal absorption device introduced in 2026. Designed as a polyurethane tampon-like product, Livy aims to absorb residual seminal fluid after penile-vaginal sex, with claims of restoring natural pH and reducing discomfort and odor. While the episode acknowledges strong evidence that semen exposure alters the vaginal microbiome and increases BV risk—both newly and recurrently—it questions whether the duration of semen presence matters, noting that no data currently supports this. Dr. Chapa cautions against overextrapolation, drawing parallels to the failed historical practice of douching, which worsened BV by stripping protective lactobacilli. He emphasizes that Livy’s marketing avoids claiming BV prevention due to lack of clinical evidence, citing only a small feasibility study (N=184). The episode concludes with a balanced, skeptical stance: while Livy may improve post-sex comfort, its long-term impact on BV recurrence remains unknown. Dr. Chapa urges clinicians and patients to remain cautious, prioritize evidence-based strategies like partner therapy (ACOG-endorsed), vaginal acidification, and probiotics, and avoid overreliance on unproven devices. Key takeaways include: semen exposure is a known BV risk factor; residence time in the vagina is unproven as a risk factor; douching is harmful and ineffective; Livy is not a proven BV prevention tool; and patients should use Livy cautiously, adhering strictly to the 15-minute limit and avoiding retention. The episode underscores the importance of critical thinking when evaluating new medical devices, especially those marketed with lifestyle or comfort claims rather than robust clinical outcomes.